Low Dose Brimonidine Ophthalmic Composition for Night Vision
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for improving night vision and visual performance in low light conditions often result in side effects such as ciliary pain, tachyphylaxis, and undesirable dimming due to the use of miotics.
Innovation Solution
A composition comprising low dose brimonidine (0.01% to 0.05% w/v) combined with a nonionic surfactant (1% to 5% w/v) and a viscosity enhancer, administered to the eye to improve night vision, sports performance, and reduce eye fatigue under low luminance conditions, with a pH ranging from 6.0 to 8.0.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional miotics are used to reduce pupil size and improve night vision, then visual performance in low light conditions improves, but side effects such as ciliary pain, tachyphylaxis, and undesirable dimming occur
Solution Approach 1:
The patent changes the concentration parameter of brimonidine from traditional higher doses to a low dose range of 0.01% to 0.05% w/v, which fundamentally alters the efficacy profile. This parameter change enables achieving the desired pupil constriction and night vision improvement while eliminating the harmful side effects associated with traditional miotic concentrations
Solution Approach 2:
The patent creates a composite formulation combining brimonidine with specific vehicles including nonionic surfactants (1% to 5% w/v) and viscosity enhancers. This composite approach modifies the drug delivery characteristics and enhances the therapeutic effect while reducing side effects, as the vehicle components work synergistically with brimonidine to achieve sustained pupil constriction without the harmful effects of traditional miotics
2Reliability
If higher concentrations of brimonidine are used to ensure sufficient pupil constriction, then night vision improvement is achieved, but side effects increase
Solution Approach 1:
The patent identifies and changes the concentration parameter to a low dose range of 0.01% to 0.05% w/v brimonidine. This parameter change is supported by the formulation science that allows achieving sufficient pharmacological effect at these low concentrations through optimized vehicle delivery, thereby maintaining pupil constriction efficacy while eliminating dose-related side effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described method effectively improves night vision and reduces eye fatigue without the side effects associated with traditional miotic use, providing sustained improvement for at least four weeks without tachyphylaxis.
Implementation Method 1
Miotics have been used to reduce pupil size, and thereby filter out peripheral corneal, corneal inlay, lenticular, or lens implant induced (post cataract surgery) aberrations
Implementation Method 2
from about 1% to about 5% w/v of a nonionic surfactant
Implementation Method 3
a viscosity enhancer
Data Source
AI summary
The present invention is directed to methods for improving night vision and visual performance in low light conditions comprising ophthalmological administration of compositions comprising low dose brimonidine and a vehicle for improved performance.